Celltrion's Herzuma (Trastuzumab Biosimilar- CT-P6) Receives EMA Approval for Breast Cancer- Metastatic Breast Cancer and Metastatic Gastric Cancer
Shots:
- The approval is based on positive opinion by CHMP (EMA) assessing Herzuma and reference trastuzumab in patients with HER2 overexpression/gene amplification tumors in breast cancer- metastatic breast cancer and metastatic gastric cancer
- The study resulted in a non-inferiority data demonstrating efficacy- safety- immunogenicity- PD and PK in patients
- Herzuma (trastuzumab biosimilar- CT-P6) is a mAb- that binds to extracellular domain of human epidermal growth factor receptor (HER2) and is currently reviewed by FDA review in the USS
Ref: Celltrion | Image: Celltrion
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com